PharmaBlock Sciences (Nanjing), Inc.

Shenzhen Stock Exchange 300725.SZ

PharmaBlock Sciences (Nanjing), Inc. Operating Cash Flow for the year ending December 31, 2023: USD 34.77 M

PharmaBlock Sciences (Nanjing), Inc. Operating Cash Flow is USD 34.77 M for the year ending December 31, 2023, a -2.71% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

PharmaBlock Sciences (Nanjing), Inc. Operating Cash Flow for the year ending December 31, 2022 was USD 35.74 M, a -4.60% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Operating Cash Flow for the year ending December 31, 2021 was USD 37.46 M, a -9.94% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Operating Cash Flow for the year ending December 31, 2020 was USD 41.59 M, a 128.00% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Operating Cash Flow for the year ending December 31, 2019 was USD 18.24 M, a -21.66% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Shenzhen Stock Exchange: 300725.SZ

PharmaBlock Sciences (Nanjing), Inc.

CEO	Dr. Minmin Yang Ph.D.
IPO Date	Nov. 10, 2017
Location	China
Headquarters	10 Xuefu Road
Employees	2,455
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Petrochemicals

Description

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years